Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Collegium Pharmaceutical (COLL) EBIT (2016 - 2025)

Collegium Pharmaceutical has reported EBIT over the past 10 years, most recently at $60.8 million for Q4 2025.

  • Quarterly results put EBIT at $60.8 million for Q4 2025, up 59.42% from a year ago — trailing twelve months through Dec 2025 was $179.6 million (up 5.73% YoY), and the annual figure for FY2025 was $179.6 million, up 5.73%.
  • EBIT for Q4 2025 was $60.8 million at Collegium Pharmaceutical, down from $62.1 million in the prior quarter.
  • Over the last five years, EBIT for COLL hit a ceiling of $62.1 million in Q3 2025 and a floor of -$34.1 million in Q4 2021.
  • Median EBIT over the past 5 years was $29.7 million (2023), compared with a mean of $28.4 million.
  • Biggest five-year swings in EBIT: tumbled 327.54% in 2021 and later skyrocketed 424.69% in 2023.
  • Collegium Pharmaceutical's EBIT stood at -$34.1 million in 2021, then surged by 134.46% to $11.8 million in 2022, then skyrocketed by 424.69% to $61.7 million in 2023, then plummeted by 38.22% to $38.1 million in 2024, then soared by 59.42% to $60.8 million in 2025.
  • The last three reported values for EBIT were $60.8 million (Q4 2025), $62.1 million (Q3 2025), and $35.1 million (Q2 2025) per Business Quant data.